Dog Immune-Mediated Haemolytic Anaemia: Welfare Through Acute Crisis and Chronic Management

IMHA is a life-threatening immune condition causing the body to destroy its own red blood cells. Understanding its welfare implications helps owners respond effectively and manage affected dogs compassionately.

Key Facts

Immune-mediated haemolytic anaemia (IMHA) involves autoantibody destruction of red blood cells, causing severe anaemia
It is one of the most common immune-mediated diseases in dogs; Cocker Spaniels, Springer Spaniels, and Poodles have elevated prevalence
Clinical signs include extreme weakness, rapid breathing, pale or yellow-tinged mucous membranes, and collapse
Without treatment, severe IMHA is fatal within days; intensive care with immunosuppression and sometimes blood transfusion is required
Corticosteroids are the mainstay of treatment; additional immunosuppressants (azathioprine, mycophenolate) reduce relapse risk
Thromboembolism — blood clot formation triggered by the disease process — is a major cause of death even in treated dogs
Relapse affects approximately 30-40% of dogs after initial remission; long-term monitoring is essential

Welfare Considerations

IMHA causes acute, severe welfare compromise. Dogs in IMHA crisis are profoundly anaemic: extreme weakness, difficulty breathing, and organ-level oxygen deprivation cause acute distress that is not subtle. The disease can progress from apparent normality to critical collapse within 24-48 hours. Treatment with high-dose immunosuppressants causes significant side effects — increased thirst, appetite, susceptibility to infection, and behavioural changes from steroid effects on the brain. Long-term management requires owners to monitor carefully for relapse signs and maintain medication compliance over months. The welfare burden of IMHA is high in the acute phase and reduces substantially with successful remission. Early recognition of recurrence signs and prompt veterinary response prevents the acute welfare crisis of severe anaemia recurring.

What You Can Do

If your dog shows sudden weakness, rapid breathing, or pale gums, seek emergency veterinary assessment immediately — IMHA can be rapidly fatal
Follow corticosteroid tapering schedules exactly as prescribed — too rapid reduction triggers relapse
Monitor mucous membrane colour and respiratory rate daily during the tapering phase as early relapse indicators
Ask your vet about thromboembolism prevention with aspirin or clopidogrel during the acute phase
Connect with IMHA dog owner communities for practical guidance on long-term management and relapse recognition